ArticleBritish journal of pharmacology2007
Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.
Article in British journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.
- A systematic review and meta-analysis of erythropoietin in experimental stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2010Pooled it
- Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.Trials · 2010Trial
- Epoetin alfa has a potent anxiolytic effect on naive female rats.BMC pharmacology & toxicology · 2025Article
- Erythropoietin for Seizures and Epilepsy: Neuroprotective Effects, Mechanisms, and Contradictory Risks.CNS & neurological disorders drug targets · 2025Review
- The effect of recombinant erythropoietin on long-term outcome after moderate-to-severe traumatic brain injury.Intensive care medicine · 2023Article
- The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review.Frontiers in pharmacology · 2022Review
- Development of a Neuroprotective Erythropoietin Modified with a Novel Carrier for the Blood-Brain Barrier.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Article
- Therapeutic effects of syringaldehyde on spinal cord ischemia in rabbits.Saudi medical journal · 2020Article
- Pre-clinical to Clinical Translational Failures and Current Status of Clinical Trials in Stroke Therapy: A Brief Review.Current neuropharmacology · 2020Review
- Effect of carbamylated erythropoietin on neuronal apoptosis in fetal rats during intrauterine hypoxic-ischemic encephalopathy.Biological research · 2019Article
- Endotoxin-induced cerebral pathophysiology: differences between fetus and newborn.Physiological reports · 2019Article
- Erythropoietin Protects Against Cognitive Impairment and Hippocampal Neurodegeneration in Diabetic Mice.Behavioral sciences (Basel, Switzerland) · 2018Article
- Carbamylated Erythropoietin Decreased Proliferation and Neurogenesis in the Subventricular Zone, but Not the Dentate Gyrus, After Irradiation to the Developing Rat Brain.Frontiers in neurology · 2018Article
- Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.Molecular brain · 2016Review
- Erythropoietin Protects Rat Brain Injury from Carbon Monoxide Poisoning by Inhibiting Toll-Like Receptor 4/NF-kappa B-Dependent Inflammatory Responses.Inflammation · 2016Article
- Beneficial Effect of Erythropoietin Short Peptide on Acute Traumatic Brain Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Article
- Parsing Physiological Functions of Erythropoietin One Domain at a Time.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Article
- A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor.Molecular pharmacology · 2015Article
- Carbamylated Erythropoietin: A Prospective Drug Candidate for Neuroprotection.Biochemistry insights · 2015Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
background and purposeRecombinant human erythropoietin (rhEPO; Epoetin-alpha; PROCRITtrade mark) has been shown to exert neuroprotective and restorative effects in a variety of CNS injury models. However, limited information is available regarding the dose levels required for these beneficial effects or the neuronal responses that may underlie them. Here we have investigated the dose-response to rhEPO and compared the effects of rhEPO with those of carbamylated rhEPO (CEPO) in a model of cerebral stroke in rats. EXPERIMENTAL APPROACH: Rats subjected to embolic middle cerebral artery occlusion (MCAo) were treated with rhEPO or CEPO, starting at 6 h and repeated at 24 and 48 h, after MCAo. Cerebral infarct volumes were assessed at 28 days and neurological impairment at 7, 14, 21 and 28 days, post-MCAo. KEY
resultsrhEPO at dose levels of 500, 1150 or 5000 IU kg(-1) or CEPO at a dose level of 50 microg kg(-1) significantly reduced cortical infarct volume and reduced neurologic impairment. All doses of rhEPO, but not CEPO, produced a transient increase in haematocrit, while rhEPO and CEPO substantially reduced the number of apoptotic cells and activated microglia in the ischemic boundary region. CONCLUSIONS AND IMPLICATIONS: These data indicate that rhEPO and CEPO have anti-inflammatory and anti-apoptotic effects, even with administration at 6 h following embolic MCAo in rats. Taken together, these actions of rhEPO and CEPO are likely to contribute to their reduction of neurologic impairment following cerebral ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.